ACTRN12605000237684已完成2 期
A blinded, randomised, placebo-controlled Phase II study to evaluate the safety and efficacy of 12.5 mcg AVAC (TM) (delipidated, deglycolipidated and arabinogalactan depleted derivative of heat-killed Mycobacterium vaccae suspension) in children with moderate-to-severe atopic dermatitis (AD)
Genesis Research & Development Corporation Ltd0 个研究点目标入组 120 人开始时间: 2005年8月26日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 5 Years 至 18 Years（—）
- 性别
- All
入选标准
- •Diagnosis of moderate-to-severe atopic dermatitis (AD). Severity defined according to Rajka and Langeland criteria; atopic dermatitis defined according to UK Atopic Dermatitis Working Party criteria.
排除标准
- •No exclusion criteria
研究者
相似试验
进行中（未招募）
1 期
Trauma Organ Protection - ArtesunateEUCTR2015-000301-40-GBQueen Mary University of London105
已完成
2 期
The TOP-ART Study: Trauma Organ Protection - ArtesunateISRCTN15731357Queen Mary University of London105
进行中（未招募）
1 期
Rescue with Regadenoson (ReWiRe)Cardiovascular collapse following traumatic haemorrhageEUCTR2018-003284-62-GBQueen Mary University London98
进行中（未招募）
1 期
A Phase 2 study of INBRX-109 in adults with a type of unresectable or metastasized cancer of the bones and joints (Conventional Chondrosarcoma).nresectable or metastatic conventional chondrosarcomaMedDRA version: 21.1Level: PTClassification code 10008734Term: ChondrosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-002635-35-ITInhibrx, INC201
招募中
2 期
A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional ChondrosarcomaConventional chondrosarcomas10005959malignant bone tumorNL-OMON54090Inhibrx, Inc.18